Highlights from the 12th World Conference on Lung Cancer - CME Chandra Belani, MD, Penn State Cancer Center, Hershey, PA; David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; David Jackman, MD, Dana-Farber Cancer Institute, Boston, MD.
Alimta® and Gemzar® Effective for Peritoneal Mesothelioma(7/22/2008) Researchers affiliated with a multicenter U.S. trial have reported that the combination of Alimta® (pemetrexed) and Gemzar® (gemcitabine) was active in patients with peritoneal mesothelioma. The details of this study appeared in the July 20, 2008 issue of the Journal of Clinical Oncology.
Navelbine® and Platinol® Effective for Mesothelioma(7/10/2008) Researchers from Denmark have reported that the combination of Navelbine® (vinorelbine) and Platinol® (cisplatin) is highly active in patients with newly diagnosed non-resectable malignant pleural mesothelioma. The details of this study appeared in an early online publication in the British Journal of Cancer on June 10, 2008.
Alimta® and Paraplatin® Effective in Elderly with Mesothelioma(7/9/2008) Researchers from Italy have reported that the combination of Alimta® (pemetrexed) and Paraplatin® (carboplatin) is effective palliative therapy for elderly patients with mesothelioma. The details of this study appeared in an early online publication in the British Journal of Cancer on June 10, 2008.
Population-based Epidemiology and Prognosis of Mesothelioma Defined(4/2/2008) Researchers from Leeds in the UK have reported that the incidence of mesothelioma is increasing and that the prognosis is worse than ascertained in selected studies from referral institutions. The details of this study appeared in an early online publication in Thorax on January 17, 2008.
Conference Coverage
Current Topics
Latest Mesothelioma News